EGFR T790M
This template is part of the ArticlePlaceholder extension. If you want to adjust it, please consider making your changes upstream.
genetic variant
estas
kromosomo
komenco de geno
fino de geno
biologia variaĵo de
pozitive indikas terapion
determina metodo: CIViC evidence level B
kuracata malsano: pulma karcinomo de nemalgrandaj ĉeloj
rating: CIViC 4-star trust rating
determina metodo: CIViC evidence level E
kuracata malsano: pulma karcinomo de nemalgrandaj ĉeloj
rating: CIViC 1-star trust rating
determina metodo: CIViC evidence level D
kuracata malsano: pulma karcinomo de nemalgrandaj ĉeloj
rating: CIViC 3-star trust rating
determina metodo: CIViC evidence level B
kuracata malsano: pulma karcinomo de nemalgrandaj ĉeloj
rating: CIViC 4-star trust rating
determina metodo: CIViC evidence level B
kuracata malsano: pulma karcinomo de nemalgrandaj ĉeloj
rating: CIViC 3-star trust rating
determina metodo: CIViC evidence level D
kuracata malsano: pulma karcinomo de nemalgrandaj ĉeloj
rating: CIViC 3-star trust rating
determina metodo: CIViC evidence level A
kuracata malsano: pulma karcinomo de nemalgrandaj ĉeloj
rating: CIViC 5-star trust rating
determina metodo: CIViC evidence level C
kuracata malsano: adenocarcinoma of the lung
rating: CIViC 1-star trust rating
determina metodo: CIViC evidence level C
kuracata malsano: adenocarcinoma of the lung
rating: CIViC 2-star trust rating
determina metodo: CIViC evidence level D
kuracata malsano: pulma karcinomo de nemalgrandaj ĉeloj
rating: CIViC 2-star trust rating
determina metodo: CIViC evidence level D
kuracata malsano: pulma karcinomo de nemalgrandaj ĉeloj
rating: CIViC 2-star trust rating
determina metodo: CIViC evidence level D
kuracata malsano: pulma karcinomo de nemalgrandaj ĉeloj
rating: CIViC 2-star trust rating
rating: CIViC 3-star trust rating
kuracata malsano: pulma karcinomo de nemalgrandaj ĉeloj
determina metodo: CIViC evidence level C
rating: CIViC 2-star trust rating
kuracata malsano: pulma karcinomo de nemalgrandaj ĉeloj
determina metodo: CIViC evidence level D
rating: CIViC 2-star trust rating
kuracata malsano: pulma karcinomo de nemalgrandaj ĉeloj
determina metodo: CIViC evidence level D
rating: CIViC 3-star trust rating
kuracata malsano: pulma karcinomo de nemalgrandaj ĉeloj
determina metodo: CIViC evidence level D
determina metodo: CIViC evidence level C
rating: CIViC 2-star trust rating
kuracata malsano: pancreatic adenocarcinoma
kontestita fare de: EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance.
negative indikas terapion
rating: CIViC 5-star trust rating
kuracata malsano: pulma karcinomo de nemalgrandaj ĉeloj
determina metodo: CIViC evidence level A
rating: CIViC 3-star trust rating
kuracata malsano: pulma karcinomo de nemalgrandaj ĉeloj
determina metodo: CIViC evidence level B
rating: CIViC 4-star trust rating
kuracata malsano: pulma karcinomo de nemalgrandaj ĉeloj
determina metodo: CIViC evidence level B
rating: CIViC 3-star trust rating
kuracata malsano: adenocarcinoma of the lung
determina metodo: CIViC evidence level B
rating: CIViC 3-star trust rating
kuracata malsano: adenocarcinoma of the lung
determina metodo: CIViC evidence level B
rating: CIViC 3-star trust rating
kuracata malsano: pulma karcinomo de nemalgrandaj ĉeloj
determina metodo: CIViC evidence level B
rating: CIViC 4-star trust rating
kuracata malsano: pulma karcinomo de nemalgrandaj ĉeloj
determina metodo: CIViC evidence level B
rating: CIViC 4-star trust rating
kuracata malsano: pulma karcinomo de nemalgrandaj ĉeloj
determina metodo: CIViC evidence level D
rating: CIViC 4-star trust rating
kuracata malsano: pulma karcinomo de nemalgrandaj ĉeloj
determina metodo: CIViC evidence level C
rating: CIViC 4-star trust rating
kuracata malsano: pulma karcinomo de nemalgrandaj ĉeloj
determina metodo: CIViC evidence level C
Referenco
- ↑ CIViC database
- ↑ 2,00 2,01 2,02 2,03 2,04 2,05 2,06 2,07 2,08 2,09 CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/variants/34
- ↑ OpenAlex, 26 jan. 2022, https://docs.openalex.org/download-snapshot/snapshot-data-format
- ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/646, Rociletinib in EGFR-mutated non-small-cell lung cancer
- ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/278, A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity
- ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/963, AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
- ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/965, AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
- ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/966, Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib
- ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/762, Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
- ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/1592, Osimertinib: First Global Approval
- ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/1867, Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
- ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/1397, Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain
- ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/2157, EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.
- ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/2162, Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.
- ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/2163, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/2164, Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models
- ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/2165, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/277, Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC.
- ↑ 19,0 19,1 CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/967, In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer
- ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/2161, PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
- ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/6006, EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance.
- ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/238, EGFR T790M resistance mutation in non small-cell lung carcinoma
- ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/239, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
- ↑ 24,0 24,1 CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/1667, Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma
- ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/240, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
- ↑ 26,0 26,1 CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/1391, Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers
- ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/1863, Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.
- ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/2160, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- ↑ 29,0 29,1 CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/2158, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
- ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/369, The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis
- ↑ CIViC database, 23 maj. 2022, https://civic.genome.wustl.edu/links/evidence/370, Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients